With a wealth of experience in biopharma and a keen eye for technological advancement, Ivan Kairatov stands at the forefront of innovation in the industry. Today, he shares his insights on the FDA's recent decision to publish complete response letters (CRLs), a move designed to enhance transparency
The field of oncology is perpetually advancing, with innovative therapies constantly emerging to tackle complex diseases like lung cancer. Ivan Kairatov, a seasoned expert in biopharma with extensive experience in technological innovations and R&D, provides insights into the recent FDA approval of
Amid growing health crises and increasing global competition in pharmaceuticals, a novel FDA initiative aims to fast-track drug reviews by slashing approval times for essential medicines. Can this new approach significantly impact domestic drug manufacturing, or does it introduce unprecedented
The 2025 ASCO Annual Meeting brought groundbreaking advances and transformative developments to the oncology sphere. The event has long been a cornerstone for introducing innovative treatment paradigms and groundbreaking research in cancer therapy. This year, the conference sustained this trend by
What if the secret to faster and more effective cancer treatments isn't found in conventional laboratories but within the algorithms of artificial intelligence instead? Drug development has long been a drawn-out process, often taking over a decade to bring a new medication from concept to market.
With over ten million people worldwide battling Parkinson's disease, the quest for a treatment that not only controls symptoms but also halts the progression of this neurological disorder is of immense importance. Roche's recent advancement of prasinezumab, developed with Prothena, into Phase 3
